# Abivax SA (ABVX)

Source: https://www.quantisnow.com/company/ABVX
Generated: 2026-11-17T03:40:30.482Z

- Ticker: ABVX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2023
- SEC CIK: 0001956827

## Latest ABVX news and filings

- 2026-11-16 23:24 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Abivax SA](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-abivax-sa-6795081)
- 2026-11-02 21:05 UTC [Conference Announcement] [Abivax to Participate in Upcoming Fall Investor Conferences](https://www.quantisnow.com/insight/abivax-to-participate-in-upcoming-fall-investor-conferences-6767004)
- 2026-09-30 20:05 UTC [Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026](https://www.quantisnow.com/insight/abivax-to-present-data-on-obefazimod-at-united-european-gastroenterology-6730565)
- 2026-09-21 20:21 UTC [SEC Form F-6EF filed by Abivax SA](https://www.quantisnow.com/insight/sec-form-f-6ef-filed-by-abivax-sa-6721741)
- 2026-09-21 20:12 UTC [SEC Form 6-K] [SEC Form 6-K filed by Abivax SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-abivax-sa-6721680)
- 2026-09-21 20:05 UTC [Public Offering] [Abivax Presents Business Updates and First Half 2026 Financial Results](https://www.quantisnow.com/insight/abivax-presents-business-updates-and-first-half-2026-financial-results-6721607)
- 2026-08-14 20:22 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Abivax SA](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-abivax-sa-6683119)
- 2026-07-30 20:05 UTC [Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod](https://www.quantisnow.com/insight/abivax-announces-positive-pre-nda-interaction-with-the-fda-for-obefazimod-6655983)
- 2026-07-23 20:05 UTC [Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments](https://www.quantisnow.com/insight/abivax-strengthens-commercial-capabilities-with-strategic-leadership-appointments-6646930)
- 2026-07-07 01:35 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Abivax SA](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-abivax-sa-6629221)
- 2026-07-06 20:05 UTC [Public Offering] [Abivax Announces Closing of $920 Million Public Offering](https://www.quantisnow.com/insight/abivax-announces-closing-of-920-million-public-offering-6628007)
- 2026-07-02 20:09 UTC [SEC Form 6-K] [SEC Form 6-K filed by Abivax SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-abivax-sa-6625288)
- 2026-07-02 20:06 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Abivax SA](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-abivax-sa-6625164)
- 2026-07-02 06:00 UTC [Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)](https://www.quantisnow.com/insight/abivax-announces-full-exercise-of-underwriters-option-to-purchase-additional-6623970)
- 2026-07-01 13:16 UTC [SEC Form FWP] [SEC Form FWP filed by Abivax SA](https://www.quantisnow.com/insight/sec-form-fwp-filed-by-abivax-sa-6622213)
- 2026-07-01 13:06 UTC [Public Offering] [Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares](https://www.quantisnow.com/insight/correction-abivax-announces-pricing-of-highly-oversubscribed-and-upsized-800m-6622189)
- 2026-07-01 12:56 UTC [Public Offering] [Abivax announces trading resumption of its ordinary shares on Euronext Paris](https://www.quantisnow.com/insight/abivax-announces-trading-resumption-of-its-ordinary-shares-on-euronext-6622119)
- 2026-07-01 12:36 UTC [Public Offering] [Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares](https://www.quantisnow.com/insight/abivax-announces-pricing-of-oversubscribed-and-upsized-800m-702m-public-6622072)
- 2026-07-01 12:18 UTC [Analyst Upgrade] [Abivax SA upgraded by Jefferies with a new price target](https://www.quantisnow.com/insight/abivax-sa-upgraded-by-jefferies-with-a-new-price-target-6621967)
- 2026-07-01 05:30 UTC [Public Offering] [Abivax announces temporary trading halt of its ordinary shares on Euronext Paris](https://www.quantisnow.com/insight/abivax-announces-temporary-trading-halt-of-its-ordinary-shares-on-6621538)
- 2026-06-30 21:29 UTC [SEC Form FWP] [SEC Form FWP filed by Abivax SA](https://www.quantisnow.com/insight/sec-form-fwp-filed-by-abivax-sa-6621343)
- 2026-06-30 21:15 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Abivax SA](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-abivax-sa-6621271)
- 2026-06-30 20:45 UTC [Public Offering] [Abivax Announces Launch of Public Offering of American Depositary Shares](https://www.quantisnow.com/insight/abivax-announces-launch-of-public-offering-of-american-depositary-shares-6621093)
- 2026-06-30 20:19 UTC [SEC Form POSASR filed by Abivax SA](https://www.quantisnow.com/insight/sec-form-posasr-filed-by-abivax-sa-6620934)
- 2026-06-29 21:22 UTC [SEC Form 6-K] [SEC Form 6-K filed by Abivax SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-abivax-sa-6619442)
- 2026-06-29 20:05 UTC [Earnings Date] [Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database](https://www.quantisnow.com/insight/abivax-reports-positive-abtect-maintenance-part-2-results-for-obefazimod-6618876)
- 2026-06-02 12:18 UTC [Analyst Downgrade] [Abivax SA downgraded by Jefferies with a new price target](https://www.quantisnow.com/insight/abivax-sa-downgraded-by-jefferies-with-a-new-price-target-6583343)
- 2026-06-02 12:17 UTC [Analyst Upgrade] [Abivax SA upgraded by Wedbush with a new price target](https://www.quantisnow.com/insight/abivax-sa-upgraded-by-wedbush-with-a-new-price-target-6583334)
- 2026-06-02 10:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by Abivax SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-abivax-sa-6582965)
- 2026-06-01 20:05 UTC [Earnings Date] [Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis](https://www.quantisnow.com/insight/abivax-announces-landmark-phase-3-abtect-maintenance-trial-results-evaluating-6581503)
- 2026-05-28 12:35 UTC [Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation](https://www.quantisnow.com/insight/phase-2-data-could-transform-these-biotechs-from-clinical-promise-6576337)
- 2026-05-22 20:12 UTC [SEC Form 6-K] [SEC Form 6-K filed by Abivax SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-abivax-sa-6569790)
- 2026-05-22 20:05 UTC [Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis](https://www.quantisnow.com/insight/abivax-presents-first-quarter-2026-financial-results-and-reports-three-year-6569526)
- 2026-05-20 20:47 UTC [SEC Form 6-K] [SEC Form 6-K filed by Abivax SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-abivax-sa-6565567)
- 2026-05-11 20:05 UTC [Abivax Announces Results of its May 11, 2026 Annual General Meeting](https://www.quantisnow.com/insight/abivax-announces-results-of-its-may-11-2026-annual-general-6544731)
- 2026-05-11 16:50 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Abivax SA](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-abivax-sa-6544356)
- 2026-05-07 20:03 UTC [SEC Form 6-K] [SEC Form 6-K filed by Abivax SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-abivax-sa-6538703)
- 2026-05-07 15:33 UTC [SEC Form 424B7 filed by Abivax SA](https://www.quantisnow.com/insight/sec-form-424b7-filed-by-abivax-sa-6538189)
- 2026-05-05 06:00 UTC [Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares](https://www.quantisnow.com/insight/abivax-announces-repurchase-of-royalty-certificates-and-pricing-of-45m-6530286)
- 2026-04-22 20:05 UTC [Abivax to Present Data on Obefazimod at Digestive Disease Week®](https://www.quantisnow.com/insight/abivax-to-present-data-on-obefazimod-at-digestive-disease-week-6510214)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ABVX
- Earnings history: https://www.quantisnow.com/earnings/ABVX
- Dividend history: https://www.quantisnow.com/dividends/ABVX
- Insider transactions: https://www.quantisnow.com/insiders/ABVX
- Options chain: https://www.quantisnow.com/options/ABVX
- SEC 8-K filings only: https://www.quantisnow.com/company/ABVX/8-k
- RSS and alerts for ABVX: https://www.quantisnow.com/docs/rss-feeds.md
